Cencora (COR) Q2 2026 earnings review
Strategic Pivot Works: Margins Expand Even as Revenue Cools
Cencora delivered a quarter of shifting dynamics: top-line growth is visibly decelerating, yet profitability is strengthening. Revenue grew just 3.8% YoY—a significant slowdown from the nearly 9% pace seen three quarters ago—dragged down by customer losses and brand conversions in the U.S. However, the transformational acquisition of OneOncology shifted the margin profile. Driven by OneOncology's integration, Adjusted Gross Margin expanded 45 basis points to 4.31%, helping Adjusted EPS rise 7.5% to $4.75. Crucially, the International segment snapped its year-long streak of profit declines, posting a 13.7% jump in operating income. Armed with a deleveraging balance sheet, management raised full-year EPS guidance and announced the resumption of share buybacks.
🐂 Bull Case
The pivot from pure wholesale distribution to higher-margin Management Services Organizations (MSOs) is paying off. OneOncology and Retina Consultants of America (RCA) drove a 45 bps expansion in adjusted gross margin, successfully offsetting the margin dilution from high-volume GLP-1 sales.
After multiple quarters of double-digit operating income declines tied to global clinical trial softness, the International segment reversed course, posting 13.7% operating profit growth.
🐻 Bear Case
The U.S. Healthcare Solutions segment—the company's largest engine—grew revenue at just 2.9%, trailing the company average of 3.8%. Prior year customer losses (grocery and oncology) continue to cap top-line momentum.
Acquisition-fueled debt is expensive. Net interest expense jumped 35% YoY to $140.5 million, consuming capital that previously shielded the bottom line through aggressive buybacks.
⚖️ Verdict: 🟢
Bullish. Management is executing flawlessly on its strategic roadmap: pruning non-core assets (MWI), expanding high-margin MSO services (OneOncology), fixing international operations, and generating enough cash flow to raise guidance and resume buybacks.
Key Themes
MSO Integration Fundamentally Alters Margin Profile
The February 2026 acquisition of OneOncology generated a massive $1.1B one-time GAAP remeasurement gain, but its true value is structural. The addition of OneOncology immediately expanded U.S. Healthcare Solutions' gross profit margins. This marks a successful execution of Cencora's strategy to capture higher-margin provider services (clinical research, revenue cycle management) via MSOs to offset the inherent low-margin nature of its core drug distribution business.
International Segment Snaps Losing Streak
Reversing trend. Following four quarters of operating income declines driven by a sluggish global clinical trial environment and price adjustments in developing markets, the International segment rebounded sharply. Q2 revenue grew 13.0% YoY, driving a 13.7% increase in segment operating income. This alleviates a major concern from FY25.
U.S. Revenue is Decelerating Fast
Decelerating. U.S. Healthcare Solutions revenue grew just 2.9% YoY—the lowest rate in over a year and significantly below the company's 3.8% average. The deceleration is tied to the 2025 losses of major grocery and oncology customers, combined with lower manufacturer prices on certain brand pharmaceuticals. The sheer volume of GLP-1 weight-loss drugs is propping up the top line, but those same drugs carry lower margins.
Shedding Non-Core Assets to Fund Buybacks
Management is honoring its promise to prune the 'Other' segment. The definitive agreement to merge MWI Animal Health with Covetrus removes a non-core asset that, while profitable, diluted focus from human specialty pharma. Crucially, Cencora announced it is now in a position to resume opportunistic share repurchases, targeting $1 billion by the end of calendar 2026. This signals confidence that post-acquisition deleveraging is ahead of schedule.
Escalating Debt Servicing Costs
Acquiring RCA and OneOncology required heavy borrowing. Net interest expense for Q2 was $140.5 million, a 35% jump from the prior year. While operating income grew to easily cover this, the higher debt load permanently increases fixed costs and makes the company more sensitive to floating rate term-loan adjustments.
Other KPIs
Increased 17.3% YoY. However, GAAP figures were heavily flattered by a massive $210.0 million LIFO credit (compared to a $39.5 million LIFO expense in the prior year). Adjusted Gross Profit, which strips out unpredictable LIFO swings, grew a still-healthy 15.7% to $3.37 billion, underscoring real structural margin improvements.
Accelerating. Adjusted operating expenses jumped 22.5% YoY, vastly outpacing the 3.8% revenue growth. This deleverage was primarily driven by the inclusion of higher-cost infrastructure and personnel from the OneOncology acquisition.
A massive anomaly compared to a $3.5M loss in the prior year. This was entirely driven by the acquisition of OneOncology, which triggered a $1.1 billion non-cash gain on the remeasurement of Cencora's existing equity method investment and the extinguishment of a put option liability.
Guidance
Accelerating slightly. The midpoint ($17.77) implies an 11.1% growth over FY25's $16.00, raised from previous guidance of $17.45-$17.75. The raise confirms OneOncology integration and International turnaround are ahead of initial base-case projections.
Stable. The company maintained its prior guidance, confirming that while Q2's 3.8% was soft, they expect H2 volume to stabilize within the targeted range.
Accelerating. Q2 U.S. operating income grew just 5.6%, so full-year guidance of 14-16% implies a dramatic acceleration in the second half of the year as the company fully integrates OneOncology and laps the difficult comps of 2025 customer losses.
Stable. Maintained from prior guidance. The 13.7% jump in Q2 gives management ample buffer to hit this full-year target, marking a successful normalization of the segment after a troubled FY25.
Key Questions
U.S. Revenue Growth Acceleration
U.S. segment revenue growth decelerated to 2.9% this quarter, yet full-year consolidated revenue guidance implies an acceleration to hit the 4-6% target. What specific catalysts in H2 give you confidence in a top-line rebound?
Margin vs. Volume Trade-off in GLP-1s
You noted higher sales of GLP-1s constrained gross margins despite overall margin expansion from OneOncology. As GLP-1 supply constraints ease, are you seeing any changes in the fee-for-service economics with manufacturers?
Remaining 'Other' Segment Strategy
With the divestiture of MWI Animal Health underway, what is the strategic roadmap and timeline for evaluating alternatives for the remaining assets in the 'Other' segment, such as Profarma and the Consulting businesses?
Capital Allocation Priority
You announced the resumption of a $1B share repurchase program by the end of 2026. How do you balance this against your elevated $140M quarterly interest expense burden and potential future M&A in the MSO space?